Lantern Pharma Earnings Call Transcripts
Fiscal Year 2026
-
Lantern leverages a proprietary AI platform to accelerate cancer drug development, with three clinical-stage drugs and a new subsidiary targeting neuro-oncology. The platform is now accessible to external researchers, opening significant market opportunities and generating revenue, while multiple FDA designations and upcoming data releases highlight strong clinical momentum.
-
AI-driven platforms have accelerated oncology drug development, reducing timelines and costs while enabling precision targeting and multiple FDA designations. Key catalysts include upcoming data for LP-300 and LP-184, the launch of Starlight Therapeutics, and the commercialization of withZeta.ai.
Fiscal Year 2025
-
Clinical programs advanced with strong trial results and multiple FDA designations, while AI platforms expanded commercially. Operating expenses fell 19% year-over-year, but additional funding is needed as cash runway extends only to late Q3 2026.
-
LP-184 demonstrated a favorable safety profile and durable disease control in heavily pretreated patients with advanced solid tumors, particularly those with DNA repair deficiencies and high PTGR1 expression. The drug shows strong preclinical and clinical efficacy, synergizes with PARP inhibitors, and is advancing to further trials with fast-track and orphan designations.
-
Q3 2025 marked a pivotal quarter with strong clinical progress, notably a 48% benefit rate in LP-184's phase I-A trial, and commercial advances in AI platforms. Net loss narrowed to $4.2M, with $12.4M in cash providing runway into Q3 2026.
-
Five monetization opportunities were outlined, including three clinical-stage drugs, an open-access AI platform, and a neuro-oncology spinout. Lead assets target high-value cancer indications, with multiple fast track and orphan designations, and the company is launching new AI tools for rare cancer drug development.
-
AI-driven oncology drug development is advancing with three clinical assets, robust patent protection, and a public AI platform module. Key clinical milestones include durable responses in NSCLC and B-cell lymphoma, with a strong financial position and upcoming data releases.
-
Q1 2025 saw major clinical and AI platform progress, with reduced net loss and strong cash reserves. Key trials for LP-184 and LP-300 are advancing, and commercialization of RADR AI modules is planned this year. Market opportunities and AI-driven efficiencies remain strong.
Fiscal Year 2024
-
AI-driven oncology drug development is accelerating, with multiple clinical programs advancing and key data readouts expected in 2024. Cash reserves of $24 million provide at least 12 months of runway, but additional funding will be needed.
-
Advanced three AI-guided oncology drugs in clinical trials, expanded into Asia, and secured FDA Fast Track and rare pediatric disease designations for LP-184. Maintained a strong cash position with $28.1 million, supporting a projected runway into late 2025.
-
Q2 2024 saw strong clinical progress, highlighted by an 86% clinical benefit rate in the HARMONIC trial and continued advancement of AI-driven oncology programs. Net loss was $4.96M, with $33.3M in cash supporting operations into Q3 2025.